(Q38749257)

6 September 2017

1 reference

title

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases (English)

1 reference

6 September 2017

4

1 reference

6 September 2017

3

Gert Van Assche

1 reference

6 September 2017

5

Marc Ferrante

1 reference

6 September 2017

Bram Verstockt

1

1 reference

6 September 2017

Barbara Deleenheer

series ordinal

2

1 reference

6 September 2017

language of work or name

English

0 references

publication date

2 June 2017

1 reference

Expert Opinion on Drug Safety

6 September 2017

published in

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

809-821

1 reference

Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Spontaneous abortion during ustekinumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Ustekinumab in Pediatric Crohn Disease Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Results at Up to 30 Years After Ileal Pouch-Anal Anastomosis for Chronic Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Secukinumab in plaque psoriasis--results of two phase 3 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Safety of secukinumab in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Secukinumab failure in Crohn's disease: the yeast connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2017.1338273

10.1080/14740338.2017.1338273

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference